Corbus Pharmaceuticals

Corbus CEO Yuval Cohen, Ph.D., will participate in a number of upcoming investor conferences including a panel discussion at the B. Riley Securities Precision Oncology & Radiopharma Investor Conference this Friday, February 28th at 8am ET. For more information: https://bit.ly/4hRwk3N

��I am encouraged by this emerging clinical data and its similarity to what has already been established for CRB-701 in China by our partner CSPC��, stated Dominic Smethurst, Chief Medical Officer of Corbus. Learn about the data presented at ASCO GU: https://bit.ly/411ERu1 #GU25

The poster titled "Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tumors" (Perez,et al) being presented today at the the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium is now available. View the poster here: https://bit.ly/4aXix9j #GU25

Corbus announced that data from its US and UK conducted first-in-human dose escalation clinical study (��Western study��) of CRB-701 (SYS6002) is being presented today at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The poster is being presented today, February 14th, between 11:30 am-12:45 pm PST. For details: https://bit.ly/411ERu1 #GU25

Attending ASCO GU? Corbus will present clinical data for CRB-701 from the Western dose escalation study tomorrow, February 14th. Learn more about the poster presentation: https://bit.ly/40Z9SyJ #GU25

Corbus today announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe of CRB-701 has been released. The corresponding up-to-date data will be presented as a poster during the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The data from 31 patients referred to in the abstract dates to September 2024; the upcoming poster presentation will include data on 38 patients as of December 2024. For details: https://bit.ly/3WUWnPl #GU25

Corbus to present a poster titled "Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tutors" at ASCO GU 2025 on Friday, February 14, 2025. Learn more: https://bit.ly/4jc9YLq #GU25

Tune-in today, February 5th at 2:30 p.m. ET for a fireside chat with Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, at the Guggenheim SMID Cap Biotech Conference. Watch the webcast here: https://bit.ly/3PTBJuT

Yuval Cohen, Ph.D., CEO of Corbus, will participate in an analyst-led fireside discussion during the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5th 2:30 p.m. ET. Register for the webcast here: https://bit.ly/3PTBJuT

We're #hiring a new Director, Clinical Quality Assurance (GCP) in Norwood, Massachusetts. Apply today or share this post with your network.